Robert Steele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Steele has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Michelle Brennan
Department of Biochemistry, Saint Louis University School of Medicine, St. Louis, Missouri
15 shared publications - Pradeep Bhartiya
Department of Pathology, Saint Louis University, St. Louis, Missouri
15 shared publications - Ranjit Ray
Department of Internal Medicine, Saint Louis University
15 shared publications - Richard J. DiPaolo
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
15 shared publications - Subhayan Sur
Department of Pathology, Saint Louis University, St. Louis, MO 63104, USA
15 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 1: MOC2 cells treated with bitter melon extract (BME) or momordicine -I (M-I). Cell number was enumerated by the Trypan blue dye exclusion method after 48 hours of treatment. The results shown are the average of three independent experiments. The small bar indicates the standard error.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 1: MOC2 cells treated with bitter melon extract (BME) or momordicine -I (M-I). Cell number was enumerated by the Trypan blue dye exclusion method after 48 hours of treatment. The results shown are the average of three independent experiments. The small bar indicates the standard error.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 2: Image showing the gating strategy of flow cytometry and cell sorting.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 2: Image showing the gating strategy of flow cytometry and cell sorting.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Head and neck cancer (HNC) is prevalent worldwide, and treatment options are limited. Momordicine-I (M-I), a natural component from bitter melon, shows antitumor activity against these cancers, but its mechanism of action, especially in the tumor microenvironment (TME), remains unclear. In this study, we establish that M-I reduces HNC tumor growth in two different immunocompetent mouse models using MOC2 and SCC VII cells. We demonstrate that the anticancer activity results from modulating several molecules in the monocyte/macrophage clusters in CD45+ populations in MOC2 tumors by single-cell RNA sequencing. Tumor-associated macrophages (TAM) often pose a barrier to antitumor effects, but following M-I treatment, we observe a significant reduction in the expression of Sfln4, a myeloid cell differentiation factor, and Cxcl3, a neutrophil chemoattractant, in the monocyte/macrophage populations. We further find that the macrophages must be in close contact with the tumor cells to inhibit Sfln4 and Cxcl3, suggesting that these TAMs are impacted by M-I treatment. Coculturing macrophages with tumor cells shows inhibition of Agr1 expression following M-I treatment, which is indicative of switching from M2 to M1 phenotype. Furthermore, the total B-cell population in M-I-treated tumors is significantly lower, whereas spleen cells also show similar results when cocultured with MOC2 cells. M-I treatment also inhibits PD1, PD-L1, and FoxP3 expression in tumors. Collectively, these results uncover the potential mechanism of M-I by modulating immune cells, and this new insight can help to develop M-I as a promising candidate to treat HNCs, either alone or as adjuvant therapy.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Head and neck cancer (HNC) is prevalent worldwide, and treatment options are limited. Momordicine-I (M-I), a natural component from bitter melon, shows antitumor activity against these cancers, but its mechanism of action, especially in the tumor microenvironment (TME), remains unclear. In this study, we establish that M-I reduces HNC tumor growth in two different immunocompetent mouse models using MOC2 and SCC VII cells. We demonstrate that the anticancer activity results from modulating several molecules in the monocyte/macrophage clusters in CD45+ populations in MOC2 tumors by single-cell RNA sequencing. Tumor-associated macrophages (TAM) often pose a barrier to antitumor effects, but following M-I treatment, we observe a significant reduction in the expression of Sfln4, a myeloid cell differentiation factor, and Cxcl3, a neutrophil chemoattractant, in the monocyte/macrophage populations. We further find that the macrophages must be in close contact with the tumor cells to inhibit Sfln4 and Cxcl3, suggesting that these TAMs are impacted by M-I treatment. Coculturing macrophages with tumor cells shows inhibition of Agr1 expression following M-I treatment, which is indicative of switching from M2 to M1 phenotype. Furthermore, the total B-cell population in M-I-treated tumors is significantly lower, whereas spleen cells also show similar results when cocultured with MOC2 cells. M-I treatment also inhibits PD1, PD-L1, and FoxP3 expression in tumors. Collectively, these results uncover the potential mechanism of M-I by modulating immune cells, and this new insight can help to develop M-I as a promising candidate to treat HNCs, either alone or as adjuvant therapy.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Head and neck cancer (HNC) is prevalent worldwide, and treatment options are limited. Momordicine-I (M-I), a natural component from bitter melon, shows antitumor activity against these cancers, but its mechanism of action, especially in the tumor microenvironment (TME), remains unclear. In this study, we establish that M-I reduces HNC tumor growth in two different immunocompetent mouse models using MOC2 and SCC VII cells. We demonstrate that the anticancer activity results from modulating several molecules in the monocyte/macrophage clusters in CD45+ populations in MOC2 tumors by single-cell RNA sequencing. Tumor-associated macrophages (TAM) often pose a barrier to antitumor effects, but following M-I treatment, we observe a significant reduction in the expression of Sfln4, a myeloid cell differentiation factor, and Cxcl3, a neutrophil chemoattractant, in the monocyte/macrophage populations. We further find that the macrophages must be in close contact with the tumor cells to inhibit Sfln4 and Cxcl3, suggesting that these TAMs are impacted by M-I treatment. Coculturing macrophages with tumor cells shows inhibition of Agr1 expression following M-I treatment, which is indicative of switching from M2 to M1 phenotype. Furthermore, the total B-cell population in M-I-treated tumors is significantly lower, whereas spleen cells also show similar results when cocultured with MOC2 cells. M-I treatment also inhibits PD1, PD-L1, and FoxP3 expression in tumors. Collectively, these results uncover the potential mechanism of M-I by modulating immune cells, and this new insight can help to develop M-I as a promising candidate to treat HNCs, either alone or as adjuvant therapy.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Head and neck cancer (HNC) is prevalent worldwide, and treatment options are limited. Momordicine-I (M-I), a natural component from bitter melon, shows antitumor activity against these cancers, but its mechanism of action, especially in the tumor microenvironment (TME), remains unclear. In this study, we establish that M-I reduces HNC tumor growth in two different immunocompetent mouse models using MOC2 and SCC VII cells. We demonstrate that the anticancer activity results from modulating several molecules in the monocyte/macrophage clusters in CD45+ populations in MOC2 tumors by single-cell RNA sequencing. Tumor-associated macrophages (TAM) often pose a barrier to antitumor effects, but following M-I treatment, we observe a significant reduction in the expression of Sfln4, a myeloid cell differentiation factor, and Cxcl3, a neutrophil chemoattractant, in the monocyte/macrophage populations. We further find that the macrophages must be in close contact with the tumor cells to inhibit Sfln4 and Cxcl3, suggesting that these TAMs are impacted by M-I treatment. Coculturing macrophages with tumor cells shows inhibition of Agr1 expression following M-I treatment, which is indicative of switching from M2 to M1 phenotype. Furthermore, the total B-cell population in M-I-treated tumors is significantly lower, whereas spleen cells also show similar results when cocultured with MOC2 cells. M-I treatment also inhibits PD1, PD-L1, and FoxP3 expression in tumors. Collectively, these results uncover the potential mechanism of M-I by modulating immune cells, and this new insight can help to develop M-I as a promising candidate to treat HNCs, either alone or as adjuvant therapy.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.